Evaluation of the Efficacy & Safety of Amustaline/Glutathione Pathogen Reduced RBCs in Complex Cardiac Surgery: the Red Cell Pathogen Inactivation (ReCePI) Study - Protocol for a Phase 3, Randomized, Controlled Trial
Authors:
- Edward L. SnyderESEdward L. Snyder
- Michael E. SekelaMSMichael E. Sekela
- Ian J. WelsbyIWIan J. Welsby
- Yoshiya ToyodaYoshiya Toyoda
- Mohamed AlsammakMAMohamed Alsammak
- Neel R. SodhaNSNeel R. Sodha
- Thomas M. BeaverTBThomas M. Beaver
- J. Peter R. PelletierJPJ. Peter R. Pelletier
- Alesia KaplanAKAlesia Kaplan
- Roman M. SniecinskiRSRoman M. Sniecinski
- T. Brett ReeceTRT. Brett Reece
- Ronald G. PearlRPRonald G. Pearl
Preprint
- 16 November 2023
- preprint
- Published by Springer Nature in Research Square
Abstract
Background Red blood cell (RBC) transfusion is a critical supportive therapy in cardiovascular surgery (CVS). Donor selection and testing have reduced the risk of transfusion-transmitted infections; however, risks remain from bacteria, emerging viruses, pathogens for which testing is not performed and from residual donor leukocytes. Amustaline (S-303)/glutathione (GSH) treatment pathogen reduction technology is designed to inactivate a broad spectrum of infectious agents and leucocytes in RBC concentrates. The ReCePI study is a Phase 3 clinical trial designed to evaluate the efficacy and safety of pathogen reduced RBCs transfused for acute anemia in CVS compared to conventional RBCs, and to assess the clinical significance of treatment-emergent RBC antibodies. Methods ReCePI is a prospective, multicenter, randomized, double-blinded, active-controlled, paralleldesign, non-inferiority study. Eligible subjects will be randomized up to 7 days before surgery to receive either leukoreduced Test (pathogen reduced) or Control (conventional) RBCs from surgery up to Day 7 post-surgery. The primary efficacy endpoint is the proportion of patients transfused with at least one study transfusion with an acute kidney injury (AKI) diagnosis defined as any increased serum creatinine (sCr) level ≥0.3 mg/dL (or 26.5 µmol/L) from presurgery baseline within 48±4 hours of the end of surgery. The primary safety endpoints are the proportion of patients with any treatment-emergent adverse events (TEAEs) related to study RBC transfusion through 28 days, and the proportion of patients with treatment-emergent antibodies with confirmed specificity to pathogen reduced RBCs through 75 days after the last study transfusion. With ≥292 evaluable, transfused patients (>146 per arm), the study has 80% power to demonstrate non-inferiority, defined as a Test group AKI incidence increase of no more than 50% of the Control group rate, assuming a Control incidence of 30%. Discussion RBCs are transfused to prevent tissue hypoxia caused by surgery-induced bleeding and anemia. AKI is a sensitive indicator of renal hypoxia and a novel endpoint for assessing RBC efficacy. The ReCePI study is intended to demonstrate the non-inferiority of pathogen reduced RBCs to conventional RBCs in the support of renal tissue oxygenation due to acute anemia and to characterize the incidence of treatment-related antibodies to RBC.Keywords
All Related Versions
- Version 1, 2023-11-16, Research Square
- Published version: Trials, 24 (1), 1.
This publication has 23 references indexed in Scilit:
- Ensuring safety of the blood supply in the United States: Donor screening, testing, emerging pathogens, and pathogen inactivationSeminars in Hematology, 2019
- Transfusion-Transmitted Hepatitis E Virus Infection in FranceTransfusion Medicine Reviews, 2019
- Amustaline‐glutathione pathogen‐reduced red blood cell concentrates for transfusion‐dependent thalassaemiaBritish Journal of Haematology, 2019
- Transfusion-Transmitted Infections Reported to the National Healthcare Safety Network Hemovigilance ModuleTransfusion Medicine Reviews, 2019
- Effects of Red-Cell Storage Duration on Patients Undergoing Cardiac SurgeryNew England Journal of Medicine, 2015
- Age of Transfused Blood in Critically Ill AdultsNew England Journal of Medicine, 2015
- Impact of preoperative serum creatinine on short- and long-term mortality after cardiac surgery: a cohort studyBritish Journal of Anaesthesia, 2015
- Treatment of whole blood (WB) and red blood cells (RBC) with S-303 inactivates pathogens and retains in vitro quality of stored RBCBiologicals, 2010
- Impact of minimal increases in serum creatinine on outcome in patients after cardiothoracic surgery: Do we have to revise current definitions of acute renal failure?*Critical Care Medicine, 2008
- Therapeutic efficacy and safety of red blood cells treated with a chemical process (S‐303) for pathogen inactivation: a Phase III clinical trial in cardiac surgery patientsTransfusion, 2005